title: Nicotine is more addictive, not more cognitively therapeutic in a neurodevelopmental model of schizophrenia produced by neonatal ventral hippocampal lesions.
abstract: Nicotine dependence is the leading cause of death in the United States. However, research on high rates of nicotine use in mental illness has primarily explained this co-morbidity as reflecting nicotine's therapeutic benefits, especially for cognitive symptoms, equating smoking with 'self-medication'. We used a leading neurodevelopmental model of mental illness in rats to prospectively test the alternative possibility that nicotine dependence pervades mental illness because nicotine is simply more addictive in mentally ill brains that involve developmental hippocampal dysfunction. Neonatal ventral hippocampal lesions (NVHL) have previously been demonstrated to produce post-adolescent-onset, pharmacological, neurobiological and cognitive-deficit features of schizophrenia. Here, we show that NVHLs increase adult nicotine self-administration, potentiating acquisition-intake, total nicotine consumed and drug seeking. Behavioral sensitization to nicotine in adolescence prior to self-administration is not accentuated by NVHLs in contrast to increased nicotine self-administration and behavioral sensitization documented in adult NVHL rats, suggesting periadolescent neurodevelopmental onset of nicotine addiction vulnerability in the NVHL model. Delivering a nicotine regimen approximating the exposure used in the sensitization and self-administration experiments (i.e. as a treatment) to adult rats did not specifically reverse NVHL-induced cortical-hippocampal-dependent cognitive deficits and actually worsened cognitive efficiency after nicotine treatment stopped, generating deficits that resemble those due to NVHLs. These findings represent the first prospective evidence demonstrating a causal link between disease processes in schizophrenia and nicotine addiction. Developmental cortical-temporal limbic dysfunction in mental illness may thus amplify nicotine's reinforcing effects and addiction risk and severity, even while producing cognitive deficits that are not specifically or substantially reversible with nicotine.
authors.affiliation: Laboratory for Translational Neuroscience of Dual Diagnosis and Development, Institute of Psychiatric Research and Training Program in Addiction Psychiatry, Indiana University Department of Psychiatry, Indianapolis, IN, USA.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Berg
authors.forename: Alena M
authors.initials: AM
authors.lastname: Sentir
authors.forename: Benjamin S
authors.initials: BS
authors.lastname: Cooley
authors.forename: Eric A
authors.initials: EA
authors.lastname: Engleman
authors.forename: R Andrew
authors.initials: RA
authors.lastname: Chambers
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D003216:Conditioning, Operant / Q000187:drug effects; D017831:Diagnosis, Dual (Psychiatry); D004195:Disease Models, Animal; D058999:Drug-Seeking Behavior / Q000187:drug effects; D006624:Hippocampus / Q000473:pathology*; D008297:Male; D018782:Maze Learning; D008569:Memory Disorders / Q000139:chemically induced; D008570:Memory, Short-Term / Q000187:drug effects; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D017207:Rats, Sprague-Dawley; D012055:Reinforcement Schedule; D012565:Schizophrenic Psychology; D012646:Self Administration; D014029:Tobacco Use Disorder / Q000473:pathology*
chemical_list: D018722:Nicotinic Agonists; D009538:Nicotine
keywords: Addiction; dual diagnosis; hippocampus; nicotine dependence; schizophrenia; self-administration
references.citation: Nat Neurosci. 2005 Nov;8(11):1465-70
references.pmid: 16251989
references.citation: Biol Psychiatry. 2001 Jul 15;50(2):71-83
references.pmid: 11526998
references.citation: Biol Psychiatry. 2004 Sep 1;56(5):308-16
references.pmid: 15336512
references.citation: Drug Alcohol Depend. 2010 Apr 1;108(1-2):141-5
references.pmid: 20079976
references.citation: Biol Psychiatry. 2010 Oct 1;68(7):674-7
references.pmid: 20678753
references.citation: Behav Brain Res. 2011 Apr 15;218(2):346-9
references.pmid: 21184782
references.citation: Neurology. 2007 Sep 4;69(10):998-1005
references.pmid: 17785668
references.citation: Neurotoxicol Teratol. 2008 Jan-Feb;30(1):1-19
references.pmid: 18380035
references.citation: Br J Psychiatry. 2013 Jan;202(1):62-7
references.pmid: 23284151
references.citation: Biol Psychiatry. 2013 Sep 15;74(6):436-43
references.pmid: 23660272
references.citation: Am J Psychiatry. 2000 Jan;157(1):115-8
references.pmid: 10618023
references.citation: Pharmacol Biochem Behav. 2007 Feb;86(2):386-94
references.pmid: 16934862
references.citation: Pharmacol Biochem Behav. 2011 Jul;99(1):87-93
references.pmid: 21527270
references.citation: J Behav Med. 2012 Apr;35(2):139-48
references.pmid: 21479646
references.citation: Neuropsychopharmacology. 1998 Apr;18(4):243-52
references.pmid: 9509492
references.citation: Pharmacol Biochem Behav. 2001 Dec;70(4):561-70
references.pmid: 11796154
references.citation: Arch Gen Psychiatry. 2010 Jun;67(6):570-7
references.pmid: 20530006
references.citation: Addict Biol. 2013 Mar;18(2):379-91
references.pmid: 22070867
references.citation: Schizophr Bull. 2008 May;34(3):555-67
references.pmid: 17984298
references.citation: Neuropsychopharmacology. 2002 Dec;27(6):889-905
references.pmid: 12464446
references.citation: Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):E563-72
references.pmid: 22331913
references.citation: Schizophr Res. 2005 Nov 15;79(2-3):323-35
references.pmid: 15961287
references.citation: Behav Brain Res. 2009 Dec 7;204(2):295-305
references.pmid: 19100784
references.citation: JAMA. 2000 Nov 22-29;284(20):2606-10
references.pmid: 11086367
references.citation: Psychopharmacology (Berl). 2007 Feb;190(3):269-319
references.pmid: 16896961
references.citation: Arch Gen Psychiatry. 2004 Nov;61(11):1107-15
references.pmid: 15520358
references.citation: Am J Psychiatry. 2003 Jun;160(6):1041-52
references.pmid: 12777258
references.citation: Br J Psychiatry. 2013 Jan;202(1):50-5
references.pmid: 23284150
references.citation: Biol Psychiatry. 2010 Apr 15;67(8):788-92
references.pmid: 19880093
references.citation: Tob Control. 2004 Jun;13(2):206
references.pmid: 15175544
references.citation: Neuropharmacology. 2008 Jun;54(8):1201-7
references.pmid: 18433806
references.citation: Neuropsychopharmacology. 1993 Aug;9(1):67-75
references.pmid: 8397725
references.citation: Am J Psychiatry. 2009 Nov;166(11):1251-7
references.pmid: 19797432
references.citation: Schizophr Bull. 2009 May;35(3):469-72
references.pmid: 19325163
references.citation: Neuropsychopharmacology. 1996 Dec;15(6):587-94
references.pmid: 8946433
references.citation: Nat Neurosci. 2011 Apr;14(4):417-9
references.pmid: 21336271
references.citation: JAMA. 2004 Mar 10;291(10):1238-45
references.pmid: 15010446
references.citation: Biol Psychiatry. 1999 Feb 15;45(4):395-402
references.pmid: 10071707
references.citation: Psychopharmacology (Berl). 1999 Oct;146(4):447-54
references.pmid: 10550495
references.citation: Biol Psychiatry. 2008 Jul 1;64(1):62-9
references.pmid: 18377874
references.citation: Neurosci Biobehav Rev. 1988 Summer;12(2):169-75
references.pmid: 2902540
references.citation: Biol Psychiatry. 2007 Oct 1;62(7):730-8
references.pmid: 17207473
references.citation: Psychopharmacology (Berl). 2010 Sep;212(1):73-83
references.pmid: 20631994
references.citation: Psychopharmacology (Berl). 2005 May;179(2):470-8
references.pmid: 15565431
references.citation: Neuropsychopharmacology. 2009 Jan;34(2):299-306
references.pmid: 18580873
references.citation: Drug Alcohol Depend. 2013 Jun 1;130(1-3):1-12
references.pmid: 23279925
references.citation: Addict Biol. 2011 Apr;16(2):251-60
references.pmid: 20731634
references.citation: Neuropsychology. 2009 Jan;23(1):71-80
references.pmid: 19210034